Our in vitro and in vivo data provide direct evidence that CRTC activation plays an essential role in the growth of LKB1-deficient lung cancer cells and revealed that targeting gain-of-function CREB activation by interfering with the CRTC-CREB interaction is a potential effective strategy in treating LKB1-inactivated lung cancers. This evidence concerns the gene CREB1 and lung cancer.